Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amido Phosphoribosyltransferase (ATase), also known as Glutamine phosphoribosylpyrophosphate amidotransferase (GPAT), is an enzyme that catalyzes the first committed step in de novo purine nucleotide biosynthesis. It converts 5-phosphoribosyl-1-pyrophosphate (PRPP) and glutamine into 5-phosphoribosylamine (PRA), glutamate, and pyrophosphate (PPi). The enzyme is composed of two functional domains: a glutaminase domain that hydrolyzes glutamine to produce ammonia, and a phosphoribosyltransferase domain that transfers ammonia to PRPP. ATase is subject to feedback inhibition by downstream products such as AMP and is a target for antifolate drugs used in cancer chemotherapy.
Inhibition of purine synthesis by blocking the first committed step, leading to decreased DNA/RNA production and cell proliferation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amido Phosphoribosyltransferase (ATase).